Eribulin mesylate (Synonyms: B1939 mesylate; E7389 mesylate; ER-086526 mesylate)

Name: Eribulin mesylate
Brand: MedChemExpress
SKU: HY-13442A
Rating: 4.5 (1 reviews)

Cat. No.: HY-13442A Purity: 99.87%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

For research use only. We do not sell to patients.

Eribulin mesylate Chemical Structure

CAS No. : 441045-17-6

Size	Price	Stock	Quantity
500 μg	USD 370	In-stock	Estimated Time of Arrival: December 31
1 mg	USD 520	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 720	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 1000	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Eribulin mesylate:

Eribulin In-stock
Eribulin-d₃ mesylate In-stock

1 Publications Citing Use of MCE Eribulin mesylate

•iScience. 6 September 2022, 105081.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Eribulin mesylate (1-100 nM; 72 h) inhibits cells proliferation, with IC₅₀s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively^[1].
Eribulin mesylate (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells^[1].
Eribulin mesylate (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells^[1].
Eribulin mesylate (1-50 nM; 12 h) does not induce senescence in LM8 cells^[1].
Eribulin mesylate (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	LM8 cells and Dunn cells
Concentration:	0, 1, 10, 100 nM
Incubation Time:	72 hours
Result:	Inhibited cells proliferation in a dose-dependent manner.

Apoptosis Analysis^[1]

Cell Line:	LM8 cells
Concentration:	0, 10, 50 nM
Incubation Time:	12, 24, 48, 72 hour
Result:	Induced early apoptosis after 12 h at the concentration of 50 nM. Not detected apoptosis at the concentration of 10 nM.

Cell Cycle Analysis^[1]

Cell Line:	LM8 cells
Concentration:	0, 10, 50 nM
Incubation Time:	12, 24, 48, 72 hour
Result:	Induced G2/M arrest by 12 h treatment with 50 nM. No G2/M arrest was induced by10 nM treatment.

In Vivo

Eribulin mesylate (1 mg/kg; i.v. once a week for 2 weeks) reduces primary tumor growth and lung metastasis of osteosarcoma in mice^[1].
Eribulin mesylate (1 mg/kg; once i.v.) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C3H/HeN mice (4-week-old) are injected LM8 cells^[1]
Dosage:	1 mg/kg
Administration:	I.v. once a week for 2 weeks
Result:	Suppressed primary tumor growth and induced apoptosis in tumor cells. Reduced lung metastasis.

Clinical Trial

Molecular Weight

826.00

Formula

C₄₁H₆₃NO₁₄S

CAS No.

441045-17-6

Appearance

Solid

Color

White to off-white

SMILES

C=C1C[C@@](CC[C@@]2(C[C@@]3([H])O4)O[C@]([C@](O[C@](C5)([H])CC6)([H])[C@@]6([H])O7)([H])[C@@]4([H])[C@]7([H])[C@@]3([H])O2)([H])O[C@@]1([H])CC[C@](C[C@@H](C)C8=C)([H])O[C@]8([H])C[C@@](O[C@H](C[C@H](O)CN)[C@@H]9OC)([H])[C@]9([H])CC5=O.CS(=O)(O)=O

Shipping

Shipping with dry ice.

Storage

-80°C, protect from light, stored under nitrogen

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (121.07 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : ≥ 100 mg/mL (121.07 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2107 mL	6.0533 mL	12.1065 mL
5 mM	0.2421 mL	1.2107 mL	2.4213 mL
10 mM	0.1211 mL	0.6053 mL	1.2107 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 5

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 6

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (285 KB) SDS (393 KB)

COA (260 KB) HNMR (314 KB) RP-HPLC (178 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10(2): 161-174. [Content Brief]

[2]. Smith, J.A., et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry, 2010. 49(6): p. 1331-7. [Content Brief]

[3]. Okouneva, T., et al., Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008. 7(7): p. 2003-11. [Content Brief]

[4]. Towle, M.J., et al., Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res, 2011. 71(2): p. 496-505. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	1.2107 mL	6.0533 mL	12.1065 mL	30.2663 mL
	5 mM	0.2421 mL	1.2107 mL	2.4213 mL	6.0533 mL
	10 mM	0.1211 mL	0.6053 mL	1.2107 mL	3.0266 mL
	15 mM	0.0807 mL	0.4036 mL	0.8071 mL	2.0178 mL
	20 mM	0.0605 mL	0.3027 mL	0.6053 mL	1.5133 mL
	25 mM	0.0484 mL	0.2421 mL	0.4843 mL	1.2107 mL
	30 mM	0.0404 mL	0.2018 mL	0.4036 mL	1.0089 mL
	40 mM	0.0303 mL	0.1513 mL	0.3027 mL	0.7567 mL
	50 mM	0.0242 mL	0.1211 mL	0.2421 mL	0.6053 mL
	60 mM	0.0202 mL	0.1009 mL	0.2018 mL	0.5044 mL
	80 mM	0.0151 mL	0.0757 mL	0.1513 mL	0.3783 mL
	100 mM	0.0121 mL	0.0605 mL	0.1211 mL	0.3027 mL

Eribulin mesylate Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Eribulin441045-17-6B1939E7389ER-086526B 1939B-1939E 7389E-7389ER086526ER 086526Microtubule/TubulinApoptosismicrotubulemetastaticbreastcancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Eribulin mesylate (Synonyms: B1939 mesylate; E7389 mesylate; ER-086526 mesylate)

Customer Review

Other Forms of Eribulin mesylate:

Eribulin mesylate Related Antibodies

1 Publications Citing Use of MCE Eribulin mesylate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Eribulin mesylate Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Eribulin mesylate Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

Request for HNMR Report